StockData
Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc (IONS) company profile

IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/302% below fair value
$27.39+0.43 (+1.59%)

Close on Nov 18, 2026Market cap $4.55BP/E –Yield –

About Ionis Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Ionis Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops, and delivers RNA-targeted medicines to treat serious and life-threatening human diseases. Its core therapeutic focus areas include neurology, cardiometabolic disorders, and select areas of high unmet patient need. The company's marketed product portfolio features therapies such as Tryngolza, Dawnzera, Wainua, Spinraza, Qalsody, Tegsedi, and Waylivra. These treatments serve patients suffering from severe conditions, including familial chylomicronemia syndrome, hereditary angioedema, hereditary transthyretin-mediated amyloidosis polyneuropathy, spinal muscular atrophy, and amyotrophic lateral sclerosis. In addition to commercializing products independently in select markets, the company partners with global pharmaceutical firms to co-develop and distribute its therapies worldwide.

The company's commercialized products and clinical operations reach patients across multiple international markets, with regulatory approvals and active distribution agreements spanning the United States, the European Union, Canada, China, Japan, the United Kingdom, and Brazil. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Ionis Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Ionis Pharmaceuticals Inc
Founded
1989
Headquarters
Carlsbad, CA
Address
2855 Gazelle Court 92010
Phone
(760) 931-9200
Employees
1,402, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
California
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
IONS
Exchange
Nasdaq
IPO date
May 17, 1991
Shares outstanding
166M, Jul 23, 2026
Public float
$5.28B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
874015
CUSIP
462222100
ISIN
US4622221004
FIGI
BBG000JH6683
Share class FIGI
BBG001SB7RD1
LEI
549300SI4ZGLG0BLUZ92
EIN
33-0336973

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brett P. MoniaChief Executive Officer, Director242,760
Eric SwayzeEVP Research22,149
Shannon L. DeversEVP, Chief Human Resources Ofc17,811
Brian BirchlerEVP, Corp and Development Ops102,883
C. Frank BennettEVP, Chief Scientific Officer75,128
Patrick R. O'NeilEVP CLO & General Counsel59,205
Holly B. KordasiewiczEVP, Chief Development Officer22,096
Joseph BaroldiEVP, Chief Business Officer53,191
Eugene SchneiderEVP, Chf Clinical Develop Ofcr77,114
Kyle JenneEVP, Chf GL Pdt Str Ofcr23,713
Elizabeth L. HougenEVP, Finance & CFO82,660
Richard S. GearyEVP, Chief Development Officer59,657
Michael R. HaydenDirector81,298
Joan E. HermanDirector51,306
Spencer R. BerthelsenDirector161,303
Ludwig HantsonDirector–
Peter N. ReikesDirector14,222
Allene M. DiazDirector13,922
Joseph Klein IiiDirector11,214
Michael J. YangDirector7,940
Joseph LoscalzoDirector54,111
B. Lynne ParshallDirector52,878
Joseph H. WenderDirector52,035

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$13.35M$42.61M$3.49M$140$125
FY2024$15.40M-$2.70M$4.07M$58$118
FY2023$12.50M$14.22M$2.70M$84$119
FY2022$7.26M$9.54M$2.80M$63$114
FY2021$13.31M-$2.60M$3.83M$50$126
FY2020$10.96M$3.44M$5.45M$94$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Brett P. Monia
Chief Executive Officer
$1.05M$2.40M$8.44M$1.44M$18.01K$13.35M-13%
Elizabeth L. Hougen
EVP, Finance and Chief Financial Officer
$729.75K$831.92K$2.30M$516.81K$43.01K$4.42M-13%
Richard S. Geary
EVP, Chief Development Officer
$622.07K$661.89K$1.63M$366.77K$47.83K$3.33M-4%
Brian Birchler
EVP, Corporate and Development Operations
$580.15K$617.28K$1.63M$366.77K$48.01K$3.25M-3%
Eric Swayze
EVP, Research
$589.01K$626.71K$1.63M$366.77K$18.01K$3.23M-6%
Patrick R. O’Neil
EVP, Chief Legal Officer and General Counsel
$611.79K$581.20K$1.63M$366.77K$18.01K$3.21M-6%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of February 19, 2026, we employed 1,402 people, the vast majority of whom reside in the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 24, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 28, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 13, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 14, 2020Tender offerThird-party tender offer for the company's shares
Dec 18, 2015Name changeName changed from ISIS PHARMACEUTICALS INC to Ionis Pharmaceuticals Inc
Jan 12, 2009Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 28, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 10, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?